Overview

Efficacy & Safety Study of Recombinant Human Erythropoietin -Alpha, in Patients With Anemia of Chronic Renal Failure

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
To establish the efficacy and Safety of rHu-EPO-alpha in patients with anemia of Chronic Renal Failure.
Phase:
Phase 3
Details
Lead Sponsor:
Cadila Pharnmaceuticals
Treatments:
Epoetin Alfa